(Amherst, NH) – Upper respiratory tract (URT) conditions including asthma and chronic obstructive pulmonary disease (COPD) continue to be a health segment that presents challenges to the caregiver community. Patient adherence with prescribing instructions and treatment protocols remains sub-optimal across all patient categories, but particularly for the young and the elderly. This has led to significant interest on the part of device and product providers toward the development of connected inhalers. These inhalers incorporate features and design elements that address patient dosing errors and treatment adherence, in the process improving patient safety.
The initial emphasis on connected oral inhalers has focused on add-on, or aftermarket, devices that are designed to wrap around the inhaler or be used as a ‘cap’ that allows the sensor(s) in the connection device to recognize when the device has been actuated. The connection device captures this information and sends it off-board to another device – typically a smartphone for relay to a data processing hub, from which patients and caregivers can access the data.
While the initial focus has been on adapting existing devices, the next generation will consist of oral inhalers with connectivity integrated into the inhaler device design. Key players in this segment include Novartis and Boehringer Ingelheim (BI), in collaboration with Qualcomm, and Aptar which is working with Propeller Health. Two major drug inhalation developers – AstraZeneca and BI - are pursuing multiple development paths by partnering with more than one technology supplier.
The market for connected inhalers is changing rapidly, with new collaborations being announced every couple of months and at least one add-on device supplier diversifying into the next-gen device integration space. Other important players in this market include Glaxo, 3M, Vectura, Gecko (now a part of Teva Respiratory), Adherium, and Cohero.
A comprehensive analysis of connected inhalers and their growing impact on respiratory therapeutic markets is included in a new and comprehensive report. The report, Connected Oral Inhalers, includes assessments of inhaler connection devices and connected inhalers, analysis of the impact of connected inhalers on URT therapeutic markets, market data and forecasts and profiles of market participants.
More information is available at
Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Source: Greystone Research Associates
For more information:
Last updated on: 18/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.